AUTHOR=Aladjidi Nathalie , Fernandes Helder , Leblanc Thierry , Vareliette Amélie , Rieux-Laucat Frédéric , Bertrand Yves , Chambost Hervé , Pasquet Marlène , Mazingue Françoise , Guitton Corinne , Pellier Isabelle , Roqueplan-Bellmann Françoise , Armari-Alla Corinne , Thomas Caroline , Marie-Cardine Aude , Lejars Odile , Fouyssac Fanny , Bayart Sophie , Lutz Patrick , Piguet Christophe , Jeziorski Eric , Rohrlich Pierre , Lemoine Philippe , Bodet Damien , Paillard Catherine , Couillault Gérard , Millot Frédéric , Fischer Alain , Pérel Yves , Leverger Guy 

TITLE=Evans Syndrome in Children: Long-Term Outcome in a Prospective French National Observational Cohort

JOURNAL=Frontiers in Pediatrics

VOLUME=Volume 3 - 2015

YEAR=2015

URL=https://www.frontiersin.org/journals/pediatrics/articles/10.3389/fped.2015.00079

DOI=10.3389/fped.2015.00079

ISSN=2296-2360

ABSTRACT=Evans syndrome (ES) is a rare autoimmune disorder whose long-term follow-up characteristics are unknown. 

Patients under 18 at the time of diagnosis of a first autoimmune cytopenia have been included since 2004 in a national prospective observational cohort. In 2014, 156 children diagnosed between 1981 and 2014 with ES, were analyzed. The median age at initial cytopenia was 5.4 (0.2-17.2) years old. For 85 sequential cases, the median delay between the episodes of AIHA and ITP was 2.4 years (0.1–16.3). The median follow-up since ES diagnosis was 6.5 years (0.1-28.8). ES revealed underlying diseases in 10% of children; in 60% of patients, various associated immune manifestations were observed, and ES remained primary in 30%. Five-year ITP and AIHA relapse-free survival were respectively 25% and 61%. In all, 69% of children required one or more than one second-line immune treatment and 15 patients (10%) died at a median age of 14.3 years (1.7-28.1).

This national work provides the first consistent clinical description for ES and underscores the high percentage of associated immune manifestations, the long-term complications, and treatment toxicities. Current challenges include the identification of underlying genetic immune dysregulations and better characterization of subgroups of patients and of second-line therapy strategies.